Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal CancerGrothey A.
Division of Medical Oncology, Mayo Clinic, Rochester, Minn., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Oxaliplatin-based chemotherapy is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC), which, in combination with targeted therapies and a sequential treatment approach using all active agents, has extended median overall survival to 2 years and beyond. Prolonged survival brings into focus the burden of treatment, in terms of associated toxicities and quality of life, and attention is now being paid to lowering the toxicity burden for patients receiving chemotherapy for mCRC without compromising efficacy. The use of oxaliplatin can lead to the development of sensory neuropathy, which commonly limits the dose and/or duration of treatment that can be administered. Temporary withdrawal of oxaliplatin (treatment holidays) has been shown to be an effective strategy for the management of this adverse effect. Data from randomized controlled trials indicate that a formalized stop-and-go approach to the delivery of oxaliplatin does not compromise efficacy, and indeed for some patients may prove beneficial by allowing them to continue treatment for longer periods. This paper presents a critical review of the evidence to support the utility of treatment interruption and reintroduction of oxaliplatin for the long-term management of mCRC.
© 2011 S. Karger AG, Basel
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
- O’Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–1425.
American Cancer Society: Cancer Facts and Figures 2006. Atlanta, American Cancer Society, 2007.
Sun W, Haller DG: The Saltz article reviewed. Oncology (Williston Park) 2005;19:1158–1160.
- Goldberg RM, Rothenberg ML, van Cutsem E, Benson ABI, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38–50.
- Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059–2069.
- De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.
- Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Cholet P, Llory JF, Letourneau Y, Coudert B, Bertheault-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–147.
Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:(abstract No. 512).
- Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30(suppl 15):5–13.
- Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S: Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6:146–151.
- Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A: Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008;26:1188–1189.
Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS: Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008;26(suppl).
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol, in press.
Cassidy J, Bjarnason GA, Hickish T, Topham C, Provencio M, Bodoky G, Landherr L, Koralewski P, Lopez-Vivanco G: Randomized double blind (DM) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral neuropathy (PSN) induced by oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in 1st line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2006;24(suppl 18S).
- Grothey A: Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005;5(suppl 1):S38–S46.
- Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003;361:457–464.
- Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
- Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672–680.
- Saif MW, Reardon J: Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005;1:249–258.
Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Louvet C, De Gramont A: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 2007;25(suppl).
- Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M: Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Chemotherapy 2008;54:395–403.
- Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G: FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006;70:345–350.
- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, De Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: a GERCOR study. J Clin Oncol 2006;24:394–400.
- Adams R, Wilson R, Seymour MT, Meade AM, Madi A, Cassidy J, Fisher D, Kenny S, Kaplan R, Maughan TS: Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). Eur J Cancer Suppl 2009;7:10.
- De Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, Tournigand C: Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007;25:3224–3229.
- Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563–572.
- Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, Barcelo R, Cervantes A, Andre T, Colin P, Louvet C, De Gramont A: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007;110:2666–2671.
Bidard F, Bengrine L, Figer A, Cervantes A, André T, Lledo G, Mabro M, Tournigand C, Louvet C, De Gramont A: Efficacy of FOLFIRI3 (irinotecan 100 mg/m2 D1, D3 combined with LV5FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the OPTIMOX1 study. J Clin Oncol 2008;26(suppl).
- Maughan T, Adams RA, Smith CG, Seymour MT, Wilson R, Meade AM, Fisher D, Madi A, Cheadle J, Kaplan R: Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer Suppl 2009;7:4.
- Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, De Gramont A: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727–5733.
Tabernero J, Aranda E, Gomez A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont M, Diaz-Rubio E: Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent BEV as maintenance therapy in patients with metastatic colorectal cancer: the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors). J Clin Oncol 2010;28(suppl 15s):abstract 3501.
de Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, André T, Larsen AK, Afchain P, Louvet C: Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol 2009;27(suppl):15s.
Chibaudel B, Tournigand C, Perez-Staub N, Bourges O, Maindrault-Goebel F, André T, Lledo G, Louvet C, Bonnetain F, De Gramont A: Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC). J Clin Oncol 2009;27(suppl):15s.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.